Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development
Journal Title: The AAPS Journal - Year 2008, Vol 10, Issue 4
Abstract
Model-based drug development (MBDD) has been recognized as a concept to improve the efficiency of drug development. The acceptance of MBDD from regulatory agencies, industry, and academia has been growing, yet today’s drug development practice is still distinctly distant from MBDD. This manuscript is aimed at clarifying the concept of MBDD and proposing practical approaches for implementing MBDD in the pharmaceutical industry. The following concepts are defined and distinguished: PK–PD modeling, exposure–response modeling, pharmacometrics, quantitative pharmacology, and MBDD. MBDD is viewed as a paradigm and a mindset in which models constitute the instruments and aims of drug development efforts. MBDD covers the whole spectrum of the drug development process instead of being limited to a certain type of modeling technique or application area. The implementation of MBDD requires pharmaceutical companies to foster innovation and make changes at three levels: (1) to establish mindsets that are willing to get acquainted with MBDD, (2) to align processes that are adaptive to the requirements of MBDD, and (3) to create a closely collaborating organization in which all members play a role in MBDD. Pharmaceutical companies that are able to embrace the changes MBDD poses will likely be able to improve their success rate in drug development, and the beneficiaries will ultimately be the patients in need.
Authors and Affiliations
Liping Zhang, Marc Pfister, Bernd Meibohm
Keywords
Related Articles
- EP ID EP681621
- DOI 10.1208/s12248-008-9062-3
- Views 90
- Downloads 0
P-gp Inhibition Potential in Cell-Based Models: Which “Calculation” Method is the Most Accurate?
The objective was to directly compare the four different “calculation” methods of assessing P-gp inhibition potential using experimental data obtained from ~60 structurally diverse internal research and m...
Preparation, characterization, and biodistribution study of technetium-99m-labeled leuprolide acetate-loaded liposomes in ehrlich ascites tumor-bearing mice
The purpose of this study was to prepare conventional and sterically stabilized liposomes containing leuprolide acetate in an attempt to prolong the biological half life of the drug, to reduce the uptake by reticuloendot...
Inhibitors of the FcRn:IgG Protein–Protein Interaction
The neonatal Fc receptor, FcRn, is responsible for controlling the half-life of IgG antibodies. As a result, inhibitors of FcRn have been investigated as a possible way to modulate IgG half-lives. Such inhibitors could h...
In Vitro Lipolysis Data Does Not Adequately Predict the In Vivo Performance of Lipid-Based Drug Delivery Systems Containing Fenofibrate
The present study investigated the utility of in vitro lipolysis performance indicators drug solubilization and maximum supersaturation ratio (SRM) for their predictive use for the in vivo performance in a minipig model....
Prediction of Drug Clearance in Children: an Evaluation of the Predictive Performance of Several Models
The online version of this article (doi:10.1208/s12248-014-9667-7) contains supplementary material, which is available to authorized users.